Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
study save search
CENTURY LITHIUM PROVIDES UPDATE ON THE FEASIBILITY STUDY
Published: 2024-04-19 (Crawled : 12:00) - prnewswire.com
CYDVF | $0.4786 -51.9% 43K
|
Non-Energy Minerals
| Email alert
Add to watchlist
LTUM | $0.0364 33.16% 230K
|
Mining, Quarrying, and Oil and ...
| Email alert
Add to watchlist
lithium update study
Todays' Top-5
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
Published: 2024-04-19 (Crawled : 11:00) - globenewswire.com
TLSA | News | $0.6698 4.66% 4.45% 600K
|
Health Technology
|
| O: 20.07%
H: 0.0%
C: 0.0%
today anti-cd3 life neurology foralumab sclerosis sciences results study
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.97 4.3% 4.12% 4.5K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
Published: 2024-04-18 (Crawled : 13:00) - biospace.com/
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -1.24%
H: 0.0%
C: 0.0%
nuzyra pre-clinical pharmaceuticals global
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
IMMP | News | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 3.69%
H: 3.56%
C: -2.22%
imp761 institute research study
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | News | $6.89 1.03% 1.02% 250K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Lantronix Case Study focuses on Reliable and Secure Support Provided to Financial Services Industry by its Out-of-Band Solutions
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
LTRX | News | $3.105 -1.43% -1.45% 150K
|
Distribution Services
|
| O: -1.27%
H: 1.28%
C: 0.96%
services solutions financial study
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
Published: 2024-04-18 (Crawled : 11:00) - biospace.com/
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
|
| O: 1.05%
H: 0.0%
C: 0.0%
obesity for study
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
EOLS | $11.49 -0.61% -0.61% 350K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: 0.0%
jeuveau publication for study
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Published: 2024-04-17 (Crawled : 16:00) - biospace.com/
HYPR | $0.855 5.56% 5.26% 57K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -8.08%
first alzheimer’s care enroll therapy study
Independent Studies Presented at ESCMID Global Demonstrate the Clinical Utility of SeptiCyte® RAPID in Patients Suspected of Sepsis, Including in Polytrauma Patients
Published: 2024-04-17 (Crawled : 13:00) - biospace.com/
EXPR | $0.77 0.0% 7.7K
|
Retail Trade
| Email alert
Add to watchlist
septicyte rapid global
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
urticaria study
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
ATAI | $1.85 -3.14% -3.24% 940K
|
Manufacturing
|
| O: 4.87%
H: 0.0%
C: 0.0%
bpl-003 life publication sciences study
Every Rand Lost to Fraud in South Africa Costs Firms R3.64 According to LexisNexis True Cost of Fraud Study
Published: 2024-04-17 (Crawled : 07:00) - prnewswire.com
RELX | $41.07 -0.87% 0.0% 1.1M
|
Commercial Services
|
| O: 1.11%
H: 0.0%
C: -1.05%
lexisnexis africa study
Every Dirham Lost to Fraud in UAE Costs Firms AED$4.19 According to LexisNexis True Cost of Fraud Study
Published: 2024-04-17 (Crawled : 05:00) - prnewswire.com
RELX | $41.07 -0.87% 0.0% 1.1M
|
Commercial Services
|
| O: 1.11%
H: 0.0%
C: -1.05%
lexisnexis study
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
VCYT | $19.43 1.2% 1.18% 1.4M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -1.41%
bladder
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
prequel positive for study
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
PALI | $4.735 -6.61% -7.07% 140K
|
Manufacturing
|
| O: 113.15%
H: 10.29%
C: -32.23%
pali-2108 study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.